Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHP-303 in Adults with Alpha-1 Antitrypsin Deficiency
2019-002501-22Phase 2Unknown
- Sponsor
- pH Pharma Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PHP-303 in alpha-1 antitrypsin deficiency (AATD) (3 arms), sponsored by pH Pharma Co., Ltd. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Status: unknown.
02
Drugs
PHP-303
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2019-002501-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002501-22.